Previous 10 |
Richland WA, July 29, 2019 (GLOBE NEWSWIRE) -- Vivos Inc . (OTCPINK: RDGL), stock symbol reverts back to RDGL effective with the open of trading on Monday, July 29. As previously disclosed, the D at the end of the stock ticker is removed 20 business days following the completion of the...
Richland, WA, June 27, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (the “ Company ”) (OTC PINK: RDGL), a company engaged in the development and commercialization of minimally invasive brachytherapy treatments to combat cancer in animals and humans, is issuing this press release to cor...
Richland, WA, June 26, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (the “ Company ”) (OTC PINK: RDGL), a company engaged in the development and commercialization of minimally invasive brachytherapy treatments to combat cancer in animals and humans, today announced that it will effect ...
Richland WA, June 18, 2019 (GLOBE NEWSWIRE) -- Vivos Inc . (OTCPINK: RDGL), Vista Veterinary Hospital obtained their license to administer IsoPet ® for animal therapy from the state of Washington. This license is an important step in our IsoPet ® commercialization plan. ...
Richland WA, April 30, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCPINK: RDGL), provides an update on the progress towards commercialization of Y-90 IsoPet ® for animal therapy. Animal Testing This week we will be treating our last dog in the test series for soft tissue sarcom...
Richland WA, March 04, 2019 (GLOBE NEWSWIRE) -- Vivos, Inc . (OTCPINK: RDGL), provides a summary of the previous update on dogs that have been treated to date in the canine soft tissue sarcoma series. Dr. Mike Korenko, Vivos Inc CEO stated “On February 25, 2019 we provided a d...
Richland WA, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Vivos, Inc . (OTC PINK: RDGL) Vivos Inc. (OTCPINK: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in animals and humans, provides this update on the dogs that ...
Richland WA, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Vivos, Inc . (OTC PINK: RDGL) . The Board of Directors of Vivos Inc. (OTCPINK: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in animals and humans, addresses its ...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- By Meg Flippin, Benzinga In what could prove to be a transformational development in cancer treatment, Vivos (OTCQB: RDGL), the maker of the Radiogel™ Precision Radionuclide Therapy, submitted an application to the U.S. Food and Drug Administration (FDA) to init...
Richland WA, June 28, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”). The filing was an amendment, addressing the FDA comments to our previous application (Q211938/S001). Today’...
Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...